Cancer chemotherapy. 3.
D000014:Abnormalities, Drug-Induced; D000477:Alkylating Agents / Q000009:adverse effects; D000493:Allopurinol / Q000008:administration & dosage / Q000627:therapeutic use; D000505:Alopecia / Q000139:chemically induced; D000963:Antimetabolites / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003520:Cyclophosphamide / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007669:Kidney Calculi / Q000378:metabolism; D007674:Kidney Diseases / Q000139:chemically induced; D007684:Kidney Tubules; D008466:Mechlorethamine / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced; D014527:Uric Acid / Q000378:metabolism; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D000477:Alkylating Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D014527:Uric Acid; D008466:Mechlorethamine; D014750:Vincristine; D000493:Allopurinol; D003520:Cyclophosphamide; D015122:Mercaptopurine